Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and beyond Targeted Therapies in Colon Cancer Today and Tomorrow

Digestive Diseases

Volumn 34, Issue 5, 2016, Pages 574-579

  Pohl, Michael ^a   Schmiegel, Wolff ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Acquired resistance; Colorectal cancer; Mismatch repair; Targeted therapies

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PD 1 ANTIBODY; PEMBROLIZUMAB; UNCLASSIFIED DRUG; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAMUCIRUMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; HUMAN; METASTATIC COLORECTAL CANCER; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; GENETICS; IMMUNOLOGY; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CETUXIMAB; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84976313070     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000445267     Document Type: Article

References (26)

1. Robert Koch-Institut: Krebs in Deutschland. 2008. http://www.rki.de/.
2. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-271.
3. Pox C, et al: [S3-guideline colorectal cancer version 1.0]. Z Gastroenterol 2013; 51: 753-854.
4. Reinacher-Schick AC, Bechstein WO: Kolorektale leberfiliae: neoadjuvante chemotherapie aus internistischer und chirurgischer sicht. Internist 2007; 48: 51-58.
5. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al: Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 1346-1355.
6. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
7. Khattak MA, Martin H, Davidson A, Phillips M: Role of first-line anti-epidermal growth factor receptor therapy compared with antivascular endothelial growth factor therapy in advanced colorectal cancer: A meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14: 81-90.
8. Cremolini C, Loupakis F, Antoniotti C, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315.
9. Cunningham D, Lang I, Marcuello E, et al: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
10. Siravegna G, Mussolin B, Buscarino M, Corti G, et al: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 795-801.
11. Montagut C, Siravegna G, Bardelli A: Liquid biopsies to evaluate early therapeutic response in colorectal cancer. Ann Oncol 2015; 26: 1525-1527.
12. Atreya CE, Van Cutsem E, Bendell JC, et al: Updated efficacy of the MEK inhibitor trametinib, BRAF inhibitor dabrafenib, and anti-EGFR antibody panitumumab in patients with BRAFV600E mutated metastatic colorectal cancer. J Clin Oncol 2015; 33(suppl): abstr 103.
13. Bertotti A, Papp E, Jones S, Adleff V, et al: The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526: 263-267.
14. Siena S, Sartore-Bianchi A, Lonardi S, et al: Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 2015; 33(suppl):abstr 3508.
15. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. J Clin Oncol 2015; 33(suppl):abstr LBA100.
16. Le DT, Uram JN, Wang H, et al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.
17. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
18. Giannakis M, Shukla S, Mu JX, et al: Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. J Clin Oncol 2015; 33(suppl):abstr 3505.
19. Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33: 4032-4038.
20. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
21. Gomez-Roca C, Delord J, Robert C, et al: Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC). Ann Oncol 2014; 25(suppl 4): iv167-iv209.
22. Corcoran RB, Atreya CE, Falchook GS, et al: Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33: 4023-4031.
23. Yaeger R, Cercek A, O'Reilly EM, et al: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-1320.
24. Tabernero J, Chan E, Baselga J, et al: VEBASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). ASCO Meeting Abstracts 2014; 32: 3518.
25. Tabernero J, van Geel R, Bendell JC, et al: Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer. Eur J Cancer 2014; 50(suppl 6); abstr 11LBA.
26. Hong DS, Morris VK, El Osta BE, et al: Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. ASCO Meeting Abstracts 2015; 33(15 suppl): 3511.